ImmunityBio, Inc.IBRXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank46
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-2.13%
↑ 71% vs avg
Percentile
P46
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-7.25%
Historical baseline
PeriodValue
Q4 2025-2.13%
Q3 202513.59%
Q2 20257.17%
Q1 2025-0.89%
Q4 202413.79%
Q3 20241.58%
Q2 20246.20%
Q1 20247.19%
Q4 2023-31.88%
Q3 2023-9.56%
Q2 20235.38%
Q1 20237.07%
Q4 2022-12.56%
Q3 202211.67%
Q2 2022-21.78%
Q1 2022-4.59%
Q4 20211.48%
Q3 2021-4.48%
Q2 2021-15.09%
Q1 2021-4.97%
Q4 2020-55.72%
Q3 202019.62%
Q2 2020-47.95%
Q1 2020-108.98%
Q4 201910.18%
Q3 20191.52%
Q2 2019-28.67%
Q1 20196.81%
Q4 201820.14%
Q3 2018-8.02%
Q2 2018-4.87%
Q1 2018-13.72%
Q4 2017-34.61%
Q3 201732.22%
Q2 2017-48.65%
Q1 20176.47%
Q4 2016-0.66%
Q3 2016-28.70%
Q2 20166.27%
Q1 201620.11%